Long-term study of LAMA2 and SELENON muscle conditions
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study follows people with LAMA2-related muscular dystrophy or SELENON-related myopathy over 5 years to understand how the condition changes over time. It may help you by tracking your disease progression and contributing to future research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of LAMA2-related muscular dystrophy or SELENON-related myopathy (two disease-causing mutations in the LAMA2 or SELENON gene).
- You must be willing and able to complete some or all of the study measurements, either at Radboudumc in Nijmegen or through home visits.
- You must speak Dutch.
- If you don't have a genetic test but have a first-degree relative with a confirmed diagnosis and typical symptoms, you may also qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with nemaline myopathy over time to understand how the condition progresses naturally. It does not test a treatment, so it helps researchers learn more about the disease.
This study follows patients with congenital myopathies to understand how their muscles get tired over time. It may help develop better treatments.
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
This study continuously measures activity and movement in people with ALS and in control participants. It aims to better understand how muscle disease changes day-to-day function, which may help improve future monitoring or care.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
Hear when a new LAMA2-related Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.